Co-morbidities increase the risk of serious infections in patients with rheumatoid arthritis treated with TNFα inhibitors

Journal of Infection

Volumn 57, Issue 5, 2008, Pages 418-420

  Davas, Evangelos M ^a   Alexiou, Ioannis ^a   Boulbou, Mary ^a   Koutroumpas, Athanasios ^a   Makaritsis, Konstantinos ^a   Stathakis, Nikolaos ^a   Sakkas, Lazaros I ^a  

^a Technical University of Larisa   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; CRYOGLOBULIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE; AGED; BLOOD ANALYSIS; BONE MARROW BIOPSY; CANDIDA ALBICANS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CONVALESCENCE; DEATH; DIABETES MELLITUS; DISEASE DURATION; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HAEMOPHILUS PARAINFLUENZAE; HUMAN; INFECTION RISK; INFECTIOUS ARTHRITIS; INTERSTITIAL LUNG DISEASE; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; LETTER; LUNG INFECTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; PNEUMOCYSTIS CARINII; PROTEIN ELECTROPHORESIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION; URINE CULTURE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55949086239     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.07.008     Document Type: Letter

References (13)

1. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
2. Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., and Symmons D.P. Rates of serious infections, including site specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 2368-2376
3. Schneeweiss S., Sotoguchi S., Weiblatt M.E., Katz J.N., Avorn J., Sax P.E., et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 56 6 (2007) 1754-1764
4. Listing J., Strangfeld A., Kary S., Ray R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologics agents. Arthritis Rheum 52 (2005) 3403-3412
5. Salliot C., Gossec L., Ruyssen-Wintrand A., Luc M., Duclos M., Guignard S., et al. Infections during tumor necrosis factor-α blocker therapy for rheumatic disease in daily practice: a systematic retrospective study of 709 patients. Rheumatology 46 (2007) 327-334
6. Doran M.F., Crowson C.S., Pond G.R., O' Fallon W.N., and Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46 (2002) 2287-2293
7. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., et al. Time-dependent increase in risk of hospitalization with infection among Swedish RA-patients treated TNF-antagonists. Ann Rheum Dis 66 (2007) 1339-1344
8. Curtis J.F., Patkar N., Xie A., Martin C., Alison J.J., Saag M., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 56 (2007) 1125-1133
9. Dixon W.G., Watson M., Lunt M., and Hyrich K.L. Rheumatoid arthritis, interstitial lung disease, mortality and anti-TNF therapy: results from the BSR biologics registry. Ann Rheum Dis 66 Suppl. II (2007) 55
10. Wolfe F., Caplan L., and Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 36 (2007) 172-178
11. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies. Analysis of 233 cases. Medicine 86 (2007) 242-251
12. Takeuchi T., Tatsuki Y., Nogami Y., Ishiguro N., Tanaka Y., Yamanaka H., et al. Post-marketing surveillance of the safety profile of infliximab in 5000 Japanese patients with RA. Ann Rheum Dis (2007 Aug 2) (Epud ahead of print)
13. Mori S., Imamura F., Kiyofuji C., and Sugimoto M. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol 16 (2006) 251-255